Abstract
Objective - To determine efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism (PDH) that have detectable tumors but no neurologic abnormalities. Design -Case series. Animals - 6 dogs with PDH that had a detectable pituitary mass on magnetic resonance images. Procedure - Radiation was delivered in 11 fractions during a 3.5-week period for a total dose of 44 Gy. Clinical signs were evaluated, a urinalysis and ACTH stimulation test were performed, and urine cortisol-to-creatinine ratio and plasma endogenous ACTH concentration were measured before, immediately after, and 1, 3, 6, 9, and 12 months after radiotherapy. Magnetic resonance imaging was repeated 1 year after radiotherapy. Results - Clinical signs of hyperadrenocorticism resolved in 3 dogs but recurred in 2 of the 3. Clinical condition of 2 dogs improved but did not return to normal. One dog did not improve. Results of ACTH stimulation tests and urine cortisol-to-creatinine ratios correlated with clinical signs. Plasma endogenous ACTH concentration transiently decreased in all 6 dogs. One year after radiotherapy, size of tumors was decreased by 25% in 2 dogs; in the other 4 dogs, tumors could no longer be detected. None of the dogs developed neurologic abnormalities. Adverse effects of radiotherapy were mild. Clinical Implications - Radiotherapy did not result in adequate control of clinical signs of hyperadrenocorticism in 5 of 6 dogs, but size of pituitary tumors was dramatically reduced. Thus, it may be reasonable to recommend radiotherapy in dogs with PDH that have pituitary tumors for which greatest vertical height is 8 mm or more.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 374-376 |
| Number of pages | 3 |
| Journal | Journal of the American Veterinary Medical Association |
| Volume | 212 |
| Issue number | 3 |
| State | Published - Feb 1 1998 |
Fingerprint
ASJC Scopus subject areas
- veterinary(all)
Cite this
Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism. / Goossens, Mariëlle M C; Feldman, Edward C; Theon, Alain P; Koblik, Philip D.
In: Journal of the American Veterinary Medical Association, Vol. 212, No. 3, 01.02.1998, p. 374-376.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism
AU - Goossens, Mariëlle M C
AU - Feldman, Edward C
AU - Theon, Alain P
AU - Koblik, Philip D.
PY - 1998/2/1
Y1 - 1998/2/1
N2 - Objective - To determine efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism (PDH) that have detectable tumors but no neurologic abnormalities. Design -Case series. Animals - 6 dogs with PDH that had a detectable pituitary mass on magnetic resonance images. Procedure - Radiation was delivered in 11 fractions during a 3.5-week period for a total dose of 44 Gy. Clinical signs were evaluated, a urinalysis and ACTH stimulation test were performed, and urine cortisol-to-creatinine ratio and plasma endogenous ACTH concentration were measured before, immediately after, and 1, 3, 6, 9, and 12 months after radiotherapy. Magnetic resonance imaging was repeated 1 year after radiotherapy. Results - Clinical signs of hyperadrenocorticism resolved in 3 dogs but recurred in 2 of the 3. Clinical condition of 2 dogs improved but did not return to normal. One dog did not improve. Results of ACTH stimulation tests and urine cortisol-to-creatinine ratios correlated with clinical signs. Plasma endogenous ACTH concentration transiently decreased in all 6 dogs. One year after radiotherapy, size of tumors was decreased by 25% in 2 dogs; in the other 4 dogs, tumors could no longer be detected. None of the dogs developed neurologic abnormalities. Adverse effects of radiotherapy were mild. Clinical Implications - Radiotherapy did not result in adequate control of clinical signs of hyperadrenocorticism in 5 of 6 dogs, but size of pituitary tumors was dramatically reduced. Thus, it may be reasonable to recommend radiotherapy in dogs with PDH that have pituitary tumors for which greatest vertical height is 8 mm or more.
AB - Objective - To determine efficacy of cobalt 60 radiotherapy in dogs with pituitary-dependent hyperadrenocorticism (PDH) that have detectable tumors but no neurologic abnormalities. Design -Case series. Animals - 6 dogs with PDH that had a detectable pituitary mass on magnetic resonance images. Procedure - Radiation was delivered in 11 fractions during a 3.5-week period for a total dose of 44 Gy. Clinical signs were evaluated, a urinalysis and ACTH stimulation test were performed, and urine cortisol-to-creatinine ratio and plasma endogenous ACTH concentration were measured before, immediately after, and 1, 3, 6, 9, and 12 months after radiotherapy. Magnetic resonance imaging was repeated 1 year after radiotherapy. Results - Clinical signs of hyperadrenocorticism resolved in 3 dogs but recurred in 2 of the 3. Clinical condition of 2 dogs improved but did not return to normal. One dog did not improve. Results of ACTH stimulation tests and urine cortisol-to-creatinine ratios correlated with clinical signs. Plasma endogenous ACTH concentration transiently decreased in all 6 dogs. One year after radiotherapy, size of tumors was decreased by 25% in 2 dogs; in the other 4 dogs, tumors could no longer be detected. None of the dogs developed neurologic abnormalities. Adverse effects of radiotherapy were mild. Clinical Implications - Radiotherapy did not result in adequate control of clinical signs of hyperadrenocorticism in 5 of 6 dogs, but size of pituitary tumors was dramatically reduced. Thus, it may be reasonable to recommend radiotherapy in dogs with PDH that have pituitary tumors for which greatest vertical height is 8 mm or more.
UR - http://www.scopus.com/inward/record.url?scp=0032004117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032004117&partnerID=8YFLogxK
M3 - Article
C2 - 9470046
AN - SCOPUS:0032004117
VL - 212
SP - 374
EP - 376
JO - Journal of the American Veterinary Medical Association
JF - Journal of the American Veterinary Medical Association
SN - 0003-1488
IS - 3
ER -